Grants and Contributions:
Title:
Design and development of antibodies for modulation of regulatory T-cell activity with application in auto-immune diseases
Agreement Number:
1033298
Agreement Value:
$338,200.00
Agreement Date:
Jul 1, 2025 - Jun 30, 2026
Description:
The project will design and evaluate various antibodies that can redirect and deliver endogenous cytokine to regulatory T-cells to induce selective activation and proliferation of these immune regulatory cells.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V7Y 1B3
Reference Number:
172-2025-2026-Q2-1033298
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
748263746
Recipient Type:
For-profit organization
Recipient's Legal Name:
Reverb Therapeutics Inc.
Federal Riding Name:
Vancouver Centre
Federal Riding Number:
59034
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710